From disease genetics to the molecular drivers of inflammation - for the first time we can use genetic insights to understand the mechanisms of disease in humans to drive a new era of medicine.
Explore More
Nucleome is an immunology company tackling the root causes of disease through a revolutionary new approach to solving human genetics. We have a deep molecular understanding of the function and importance of the non-coding genome and how variation within it causes disease. Nucleome has created transformative 3D genomics technology to link disease-associated genetic variants with the genes they dysregulate in disease.
At the core of this, is the ability to read 3D interactions in the non-coding genome with a precision and scale that is unique in both industry and academia. We are the first company to build at scale a rich data atlas of immune system dysregulation identified from human disease genetics, allowing us to elucidate the mechanistic basis of disease, identify hundreds of novel targets and group patients by their common, mechanistic disease drivers. We are using the atlas to build a pipeline of genetically identified therapeutics to restore health in inflammatory diseases.
There is a vast amount of naturally occurring genetic variation that contributes to the risk of disease in humans, yet very little of it directly affects genes. Instead, the majority of these variants alter switches (regulatory regions) responsible for controlling the activity of genes (gene regulation). These switches are hidden in the non-coding genome, which was previously dismissed as junk DNA, and are notoriously challenging to investigate.
Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of inflammatory disease from human genetics. This has allowed us to identify functional variants in the non-coding genome and the genes that they control, enabling the discovery of novel targets and disease mechanisms that remain invisible to others.
Located in Oxford, UK, Nucleome occupies state-of-the art private laboratories, where our team of expert scientists validate these findings through the pioneering functional genomics technologies to select optimal targets for Nucleome development or pharmaceutical partnership.
We are building a first-in-class immunology pipeline with an initial focus in inflammatory diseases. Our approach identifies causal genes that drive inflammation, which if successfully targeted will restore immune homeostasis and health. Lead candidate NTP464 is anticipated to enter the clinic in 2027.
June 14, 2026
May 12, 2026
March 11, 2026